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Lay summary: 
Fatty liver disease caused by overweight with diabetes and high risk of heart attack, termed 
non-alcoholic steatohepatitis (NASH), is the most common serious liver disease but there is 
no treatment. The causes of inflammation in NASH may be several, but activation of a 
protein scaffold within cells termed the inflammasome (NLRP3) has been suggested to play a 
role. Here we show that cholesterol crystals could be one pathway to inflammasome 
activation in NASH. We then used a drug called MCC-950 which has already been shown to 
block NLRP3 activation, in an attempt to reduce liver injury in NASH. This drug partly 
reversed liver inflammation, particularly in obese diabetic mice that most closely resemble 
the human context of NASH. In addition, such dampening of liver inflammation in NASH 
achieved with MCC950 partly reversed liver scarring, the process that links NASH to 
development of cirrhosis.  
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Abstract  
 
Background and Aims: NOD-like receptor protein 3 (NLRP3) inflammasome activation 
occurs in NAFLD. We used the first small molecule NLRP3 inhibitor, MCC950, to test 
whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two 
murine models of steatohepatitis.  
Methods: We fed foz/foz and wildtype (Wt) mice atherogenic diet 16 weeks, gavaged 
MCC950 or vehicle until 24 weeks, then determining NAFLD phenotype. In mice fed 
methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle 6 weeks and 
determined effects on liver fibrosis.  
Results: In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1, active 
caspase-1 and IL-1 increased at 24 weeks, in association with cholesterol crystal formation 
and NASH pathology; plasma IL-1, IL-6, MCP-1, ALT/AST all increased. MCC950 
treatment normalized hepatic caspase 1 and IL-1 expression, plasma IL-1, MCP-1 and IL-
6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as 
NASH pathology, and liver fibrosis. In vitro, cholesterol crystals activated Kupffer cells and 
macrophages to release IL-1; MCC950 abolished this, and associated neutrophil migration. 
MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in 
hepatic caspase 1 and IL-1, lowered numbers of macrophages and neutrophils in the liver, 
and improved liver fibrosis.  
Conclusion: MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and 
fibrosis in obese diabetic mice, and this is potentially attributable to blockade of cholesterol 
crystal-mediated NLRP3 activation in myeloid cells. MCC950 reduced liver fibrosis in 
MCD-fed mice. Targeting NLRP3 is a logical direction in pharmacotherapy of NASH. 
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Non-alcoholic fatty liver disease (NAFLD) increases standardised mortality from 
cardiovascular events, common cancers, cirrhosis and hepatocellular carcinoma [1,2]. 
Adverse liver outcomes are confined to the 10-25% of NAFLD patients with liver fibrosis, 
particularly with the pathology of steatohepatitis (NASH) [3,4]. NASH occurs when 
overnutrition is complicated by insulin resistance and metabolic syndrome [2,5,6], 
particularly with a personal or family history of type 2 diabetes. Despite these connections, 
detailed mechanisms linking metabolic obesity to liver pathology are unclear. The most 
compelling concept is that hepatocyte injury results from lipotoxicity, a consequence of 
accumulated toxic lipid species [6,7]. Lipotoxicity, via release of danger-activated molecular 
patterns (DAMPs) from injured hepatocytes, and the gut microbiome via release of pathogen-
activated molecular patterns (PAMPs) such as lipopolysaccharide (LPS) activate innate 
immunity to cause liver inflammation [8-10]. 
 
Innate immunity involves signalling via pattern recognition receptors, such as the Toll-like 
receptors (TLRs). During the last few years another trigger for liver inflammation in NAFLD 
has been identified as the NOD-like receptor protein 3 (NLRP3) inflammasome [11-22]. 
Inflammasomes are multiprotein scaffolds that respond to noxious signals (PAMPs, DAMPs) 
to recruit the adapter protein ASC and pro-caspase 1, thereby activating caspase 1 by 
autocatalysis [18,21,22]. Since the outcomes include programed cell death (pyroptosis), 
inflammation and fibrosis [16,19,22], the threshold for inflammasome activation requires a 
double activation signal. For the NLRP3 inflammasome, which is highly expressed in liver, 
the first signal is often LPS, but TNF- and IL-1 are among other signal-1 molecules 
pertinent to NASH [16,19,22]. Factors that potentially provide the second signal include 
ATP, amyloid, uric acid and cholesterol crystals [23,24], while oxidative stress and potassium 
ion transport are related to the effector pathways of NLRP3 activation. In dietary and nutrient 
deficiency fatty liver diseases, increased hepatic expression of Nlrp3, Asc and Casp1 
accompanies liver inflammation [11,14,18,25].  NLRP3 activation occurs in human NASH 
[11,20], while experiments in Nlrp3
-/-
, Casp1
-/-
 and Asc
-/-
 mice indicate NLRP3 activation is 
mechanistically important for NAFLD [11,13,20].  Until now, however, it has not been 
possible to test whether requirement for NLRP3 activation in the initiation and perpetuation 
of liver inflammation in NASH is obligatory, using intervention experiments. Further, we 
note that earlier studies did not use mice with metabolic syndrome, the invariable context of 
NASH in humans [1,2,5,6]. Development of MCC950 as a first-in-class, highly potent and 
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selective small molecule inhibitor of NLRP3 [26], and characterization of a hyperphagic 
obesity mouse model of NASH linked to type 2 diabetes and metabolic syndrome [27-30], 
allowed us to conduct such studies, as reported here.  
 
Cholesterol crystals activate NLRP3 in LPS-exposed macrophages [23,24]. Recently, 
cholesterol crystals have been observed in livers of human NASH and murine NASH models, 
including the one used for the present experiments [27,31]. Here, we first showed that 
cholesterol crystals activate NLRP3 in LPS-exposed Kupffer cells (KCs), bone marrow 
macrophages (BMMs), but minimally (if at all) in hepatocytes; 10 nM MCC950 inhibited 
such activation, as well as resultant neutrophil migration in response to conditioned media 
from macrophages exposed to cholesterol crystals. We then conducted simultaneous studies 
in San Diego, CA and Canberra, Australia to test efficacy of MCC950 for preventing or 
reversing liver injury, inflammation and fibrosis in two entirely different models of 
experimental steatohepatitis. Appetite-defective foz/foz mice are an over-nutrition model in 
which NASH accompanies onset of obesity and its metabolic complications, including 
diabetes and hypercholesterolemia [27-30]. The methionine and choline deficient (MCD) 
dietary model causes severe steatohepatitis with liver fibrosis, whose pathogenesis involves 
hepatic oxidative stress as observed in human NASH [32,33]. Taken together, these novel 
findings provide robust support for the proposal that pharmacological blockade of NLRP3 
activation in the liver can improve NASH pathology and modulate other forms of 
steatohepatitis, including its most critical outcome of liver fibrosis.  
 
Methods 
Animal models  
Animal experiments were approved by Animal Experimentation Ethics Committees of 
Australian National University (Canberra) and UC San Diego.  
Atherogenic diet-fed foz/foz model. Groups (n=11-13) of female Alms1 mutant (foz/foz) mice 
or wildtype (Wt) littermates were fed atherogenic diet (23% fat, 45% carbohydrate, 20% 
protein, 0.2% cholesterol; SF03020, Specialty Feeds, Glenn Forrest, Western Australia) for 
16 weeks, when foz/foz mice weighed >60 g and exhibited hyperinsulinemia, diabetes, 
hypertension, hypercholesterolemia, hypoadiponectinemia, and NASH with fibrosis [29,30]. 
From 16 weeks, mice were gavaged MCC950 (20 mg/kg body weight) or vehicle (0.9% 
NaCl) every day, 5 days/week until 24 weeks (Suppl. Fig. 1A). Venous blood (~0.2 mL) were 
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obtained by cheek bleeding at 15 and 20 weeks. At 24 weeks, mice were fasted 4h to 
determine blood glucose (Accu-Check glucometer, Roche Diagnostics), anesthetized 
(ketamine and xylazine), plasma and liver collected and processed for histological and 
molecular readouts [29,30]. 
Methionine and choline deficient diet model. Since 2000 [32], this model has been used 
extensively to cause severe steatohepatitis and fibrosis, resembling human NASH pathology 
[28]. Groups (n=8) of 8-week-old male C57BL/6(B6) mice were placed on MCD diet 
(TD90262, Teklad Mills, Madison, WI), controls were fed the identical diet supplemented 
with methionine and choline (MCS) (TD94149, Teklad Mills). MCD-fed mice and MCS 
controls were divided into groups receiving MCC950 (10 mg/kg body weight in 0.9% NaCl 
every day for 5 days, followed by 20 mg/kg every second day up to 6 weeks), or vehicle by 
gavage. At the end of experiments, mice were anesthetized, liver and plasma collected 
[19,20]. In a second experiment, mice (n=5-6/group) were fed MCD diet for 6 weeks, during 
the last 2 weeks they were gavaged every day with MCC950 (20 mg/kg) or vehicle before 
experiments were completed.  
 
Cholesterol crystal preparation 
Hydrated cholesterol crystals, prepared as described [24], were homogenized to obtain 
crystals <10 m in diameter, and suspended in culture media before addition to cells. 
 
Isolation and culture of bone marrow-derived macrophages, primary hepatocytes, Kupffer 
cells, and neutrophil chemotaxis studies 
Using 8-10 week-old female B6 mice, bone marrow cells were extracted and differentiated (7 
days) into BMMs in murine L929 media (diluted 1:10 in RPMI with 10% FBS). Morphology 
was checked by Wright-Giemsa staining, phenotype by Mac1 and F4/80 double-positive cells 
(flow cytometry). In selected experiments, we isolated/cultured BMMs from Tlr4
-/-
 mice (gift 
of Shaun Summers, Monash Medical Centre, Clayton, VIC), and Myd88
-/-
 mice (Australian 
Phenomics Facility, Canberra), all B6. Hepatocytes were isolated by collagenase perfusion 
[30,34], seeded onto plates coated with collagen (Gibco, Carlsbad, CA), and cultured in 
Williams’ E with 1% bovine serum albumin (Sigma-Aldrich, St Louis, MO), 10 mM HEPES, 
10 mM nicotinamide, 100 U/mL penicillin and 100 μg/mL streptomycin. KCs were isolated 
from non-parenchymal cells of collagenase-perfused mouse liver [35]. Following pre-
incubation with LPS (50 pg/mL) for 1h (followed by washing), cholesterol crystals were 
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added at concentrations indicated in figure legends. We measured NLRP3 activation and 
inhibition by 10 nM MCC950 as IL-1 release into culture medium (ELISA). Neutrophil 
chemotaxis was performed as described [36] using recombinant mouse(rm)-TNF as positive 
chemoattractant. 
 
Analysis of plasma proteins  
Plasma insulin, adiponectin, monocyte chemoattractant protein (MCP)-1, IL-1, IL-6 and IL-
18 were measured by ELISAs (Insulin, Millipore, USA; others, R&D Systems, Minneapolis, 
MN). 
 
Assessment of liver injury, liver pathology and fibrosis 
Plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assayed 
by auto-analyser (Clinical Chemistry, ACT Pathology). Liver samples were fixed in 10% 
neutral-buffered formalin and paraffin embedded. H&E-stained liver sections were assessed 
blind by an experienced liver pathologist (MMY) for steatosis, inflammation and ballooning, 
combined as NAFLD activity score (NAS), and designation as: “definite NASH”, “borderline 
NASH”, “NAFLD but not NASH”, or “not NAFLD”. To demonstrate fibrosis, liver sections 
were stained 2h with picric acid containing 0.1% fast green and 0.1% Sirius red. Fibrosis 
severity determined by collagen densitometry [30,37].  
Hepatic proteins  
Hepatic proteins were estimated by Western immunoblot, [19,20,29,30,37] (antibody 
conditions provided on request). For tissue protein expression studies, immunohistochemistry 
was performed [12,19,20,30,31,37]. NF-κB p65 positive nuclei (in hepatocytes and 
inflammatory cells) and MPO positive neutrophils were counted and numbers expressed per 
100 hepatocytes. F4/80-positive staining was used to identify activated macrophages and KCs 
surrounding steatotic hepatocytes to form crown-like structures (CLS). For each liver section, 
10 random fields (400x magnification) were counted and mean value used.   
 
Hepatic mRNA expression  
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We determined hepatic expression of specific mRNAs by reverse-transcriptase quantitative 
PCR (RT-qPCR), following extraction of total RNA from liver tissue [19,20]. Primer 
sequences in Suppl. Table 1. Expression of mRNA was relative to 2-microglobulin (B2M).  
 
Statistical analyses 
For experiments involving 2 groups where distribution of data was not clearly parametric, 
Mann-Whitney U tests were performed with GraphPad Prism Software Inc, CA, Version 
5.03. For experiments involving 3 or more groups, data were evaluated using one-way 
ANOVA with multiple comparison post hoc analysis. Data are expressed as mean ± SEM, or 
as absolute number or percentage for categorical variables. The number of animals or 
measurements in each group is indicated in the figure legends. The significance level was set 
at  = 5% for all comparisons. 
 
Results 
Cholesterol crystals activate NLRP3 in wildtype but not Myd88
-/-
 macrophages, Kupffer cells 
and hepatocytes The high free cholesterol content of human and foz/foz mouse NASH 
livers [30,38-41] results in cholesterol crystallization [27,31]. Cholesterol crystals activate 
NLRP3 in LPS-primed macrophages [23,24]. We first demonstrated such activation 
(measured as IL-1 release) (Fig. 1A) and showed it is substantially inhibited by 10 nM 
MCC950 (Fig. 1B). Culture supernatant from crystal-exposed BMMs stimulated neutrophil 
chemotaxis; prior addition of MCC950 blocked this effect (Fig. 1C). Addition of cholesterol 
crystals to KCs produced similar results, albeit the magnitude of IL-1 release was less (Fig. 
1D vs 1B). We conducted identical experiments on BMMs from Tlr4
-/-
 or Myd88
-/-
 mice. 
Lack of TLR4 reduced IL-1 release, while MYD88 was essential for LPS priming of 
macrophages to release IL-1 in response to cholesterol crystals (Fig. 1A). Addition of 
crystals to LPS-primed hepatocytes appeared to cause dose-dependent IL-1 release, but the 
quantum was much less than for KCs and close to the limit of sensitivity for IL-1 detection 
(Fig. 1E vs 1D). 
 
MCC950 exhibits good bioavailability after gavage to mice  MCC950 has excellent 
microsomal stability, does not inhibit major CYP isoforms, has 70% oral bioavailability and a 
half-life of 3.2 h after oral dosing in mice [26]. For logistic and animal health reasons we 
chose to conduct daily administration of drug or vehicle (rather than twice daily). We 
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therefore measured blood levels following gavage of a single dose (20 mg/kg body weight) to 
foz/foz or Wt mice. As shown in Suppl. Fig. 1B, high blood levels of MCC950 were evident 
at 1h with no change by 4h and appreciable trough levels at 24h. 
 
Treatment with MCC950 blocks hepatic NLRP3 expression and activation in NASH  To 
test whether MCC950 can block cholesterol crystal-mediated activation of NLRP3 in intact 
livers with NASH (crystals shown in Suppl. Fig. 2A), we fed foz/foz mice atherogenic diet 16 
weeks to cause NASH [29,30,37], then gavaged animals with MCC950 or vehicle another 8 
weeks (experimental design summarized in Suppl. Fig 1A). Livers of vehicle-treated foz/foz 
mice with NASH exhibited substantial increases in NLRP3 (Fig. 2A), active caspase 1 (but 
not pro-caspase 1), pro-IL-1 and IL-1 (Fig. 2B-F). MCC950 reduced expression of all 
proteins (except pro-IL-1 to values in vehicle-treated Wt mice (Figs. 2A-F). At 24 weeks, 
there was a significant increase in circulating IL-1 in vehicle-treated foz/foz mice with 
NASH compared to Wt mice with simple steatosis; MCC950 prevented this increase (Fig. 
3A). There were no significant changes in IL-18 between groups (Fig. 3B).  
 
Treatment with MCC950 ameliorates liver injury and inflammation in two murine 
steatohepatitis models  In atherogenic diet-fed foz/foz mice gavaged with vehicle, 
plasma ALT and AST increased substantially at 16 weeks compared to Wt mice fed the same 
diet, with further rise by 24 weeks (Fig. 3C,D). Administration of MCC950 abrogated the 
increase in ALT and AST between 16 and 24 weeks in foz/foz mice, and also the moderate 
further increase in Wt mice (Fig. 3C,D). MCC950 did not cause weight loss in foz/foz or Wt 
mice (Suppl. Fig. 3A). There was also no reduction of hepatomegaly (Suppl. Fig. 3B), or in 
fasting blood glucose, plasma insulin, adiponectin, cholesterol, or triglyceride (Suppl. Fig. 
3C-F). Consistent with this lack of effect on metabolic indices and our earlier observation 
that insulin drives hepatic cholesterol accumulation [30], there was no difference in 
cholesterol crystal numbers between livers of MCC950- and vehicle-treated foz/foz mice 
(Suppl. Fig. 2B). In contrast to this lack of effect on the “metabolic drivers” of NASH 
pathogenesis [6], MCC950 lowered plasma MCP-1 and IL-6 levels (Fig. 3E,F). Likewise, 
whereas blinded semiquantitative analysis of liver histology showed no effect of MCC950 on 
steatosis score (Fig. 4A(i)), there was reduction of liver inflammation (Fig. 4B), and a strong 
trend (not significant) for less ballooning (Fig. 4A(ii)) and lower overall NAFLD activity 
score (NAS) (Fig. 4A(iii)). The effects of MCC950 on liver inflammation were supported by 
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significant (~50%) suppression of nuclear NF-B p65 expression (in hepatocytes and 
inflammatory cells), and in the number of MPO-positive cells (neutrophils) and F4/80-
positive cells (macrophages/ activated KCs forming crown-like structures [CLS]) (Fig. 4C-
E). Importantly, global assessment of liver pathology as “definite NASH”, which was 64% in 
vehicle-treated foz/foz mice, appeared to be less (18%) in MCC950-treated animals, although 
likely because of the relatively small numbers this apparent difference was not significant 
(Table 1). 
 
The MCD model shows severe steatohepatitis but is not caused by over-nutrition or 
associated with insulin resistance [28,32,42,43]. Levels of active caspase 1 and IL-1, and 
Asc, Casp1 and Il1b mRNA expression were all higher in livers of MCD-fed vs MCS-fed 
mice. Gavaging MCC950 for 6 weeks significantly lowered their expression (Fig. 5A).  As 
reported [28,32,42,43], MCD diet-fed mice lost weight compared with controls, but MCC950 
exerted no separate effect on body weight (data not shown). Livers of MCD-fed mice showed 
steatosis with severe lobular inflammation (Fig. 5B), though at the dose used for these 
experiments (effectively half that used for foz/foz mice – see Methods) there was no effect of 
MCC950 on plasma ALT. Hepatic infiltration with neutrophils (MPO) and total macrophages 
(F4/80) indicated by immunohistochemistry (Fig. 5B), and relevant mRNA transcripts for 
F4/80, MPO and infiltrating macrophages (Ly6c mRNA) increased in MCD vs MCS mouse 
liver (Suppl. Fig. 4); MCC950 partially (significantly) corrected over-expression of these 
inflammatory markers (Fig. 5B; Suppl. Fig. 4).  
 
MCC950 retards development of liver fibrosis in MCD diet-induced steatohepatitis and in 
foz/foz mice with NASH  As expected, MCD diet-fed mice showed increased collagen 
deposition by Sirius red staining (Fig. 5C), with corresponding increases in Col1a1, 
connective tissue growth factor (Ctgf) and tissue inhibitor of matrix metalloproteinase 1 
(Timp1) transcripts compared to MCS controls (Fig. 5D). Treatment with MCC950 for 6 
weeks appeared to decrease hepatic fibrosis by Sirius red densitometry (Fig. 5C), and 
significantly reduced hepatic expression of the aforementioned pro-fibrotic markers (Fig. 
5D). In case the dose regimen selected for these experiments was suboptimal (compared with 
that used for foz/foz mouse experiments), we repeated this experiment using the same dose 
(20 mg/kg body weight) as in foz/foz mice administered by gavage once a day for 2 weeks, 
starting 4 weeks after mice had been fed MCD diet. There appeared to be substantial Sirius 
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red-positive material in liver sections of vehicle-treated controls and very little in MCC950-
treated mice, although the apparent difference in collagen density fell short of significance 
(p=0.056) (Suppl. Fig. 5B). 
 
An ideal anti-inflammatory approach to NASH treatment would not only prevent fibrosis 
development it would also arrest or reverse established liver fibrosis. To test this, we 
administered MCC950 to foz/foz mice already fed atherogenic diet 16 weeks (Suppl. Fig. 
1A), at which time fibrotic NASH is established, as confirmed by substantial collagen 
deposition (Sirius red densitometry) in vehicle-treated mice (Fig. 6A,B). Following treatment 
for 8 weeks with the NLRP3 inhibitor, there was ~33% reduction in macroscopic liver 
fibrosis compared to vehicle-treated controls (Fig. 6A,B), accompanied by significant (but 
incomplete) suppression of collagen 1 expression, reduced HSC activation (as alpha-smooth 
muscle actin [-SMA] expression) and hepatic CTGF (Fig. 6C-F).  
 
 
Discussion 
The most important finding in these studies is that pharmacological inhibition of NLRP3 in 
vivo reduces liver inflammation and hepatocyte injury in metabolic syndrome-related 
NAFLD with significant reduction in resultant liver fibrosis. Hepatic NLRP3 expression 
increases during development of experimental and clinical NAFLD [11,13,14,18-20,25], and 
mice deficient in NLRP3 (Nlrp3
-/-
) or its essential components (Asc
-/-
 and Casp1
-/-
 mice) are 
protected against fatty liver disease caused by high fat or nutrient-deficient diets [12,14,20]. 
The present experiments employed atherogenic diet-fed foz/foz mice, a NASH model in 
which animals develop severe obesity, metabolic syndrome and diabetes. In this clinically 
relevant model, we showed induction of NLRP3 and evidence of its activation in liver (active 
caspase 1, IL-1) in mice with NASH; MCC950 blocked such activation of the NLRP3 
inflammasome in liver tissue, with resultant suppression of macrophage (with CLS 
formation) and neutrophil recruitment. Pharmacological NLRP3 blockade also reduced 
hepatic expression of pro-IL-1 and normalized hepatic and circulating IL-1, IL-6 and 
MCP-1 levels; pro-IL-1 and MCP-1 synthesis is regulated by NF-B, whose nuclear 
expression was also suppressed substantially in these experiments [9,18,22,44]. Hepatic 
NLRP3 expression was also suppressed by MCC950 treatment, most likely because 
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decreased production of IL-1 was, at least in part, responsible for the observed dampening 
of NF-B activation. In the MCD model, NLRP3 inflammasome inhibition similarly reduced 
macrophage and neutrophil infiltration into the liver. Together, these data provide compelling 
evidence to support earlier work in gene-deleted and dietary models for a central pro-
inflammatory role of NLRP3 activation in pathogenesis of NASH.  
 
Our in vitro studies combined with the observed effects of MCC950 in vivo may provide 
some insight into why NLRP3 is activated in NASH livers. A dual signal is required to 
promote NLRP3 macromolecular assembly and caspase 1 activation [16,18,21,22]. It seems 
possible that gut-derived PAMPs, such as LPS used in our in vitro experiments, play such a 
role in NASH [45,46]. Additional signal-1 molecules include TNF- and IL-1. Signal-2 
molecules relevant to NASH include crystals and ATP. We showed earlier, and confirmed 
here (Suppl. Fig. 2A), that cholesterol crystals form in hepatocytes in foz/foz mice as well as 
human NASH [27,31]. These crystals could play their most critical role when hepatocytes 
undergo necrotic cell death as part of lipotoxicity [34], releasing crystals into the surrounding 
tissue [47] where they are taken up by KCs and infiltrating macrophages, thus activating 
NLRP3 with release of large quanta of IL-1. Here we used cholesterol crystals to activate 
NLRP3 in macrophages and Kupffer cells in vitro, simulating the likely uptake of such 
crystals in the intact liver. We showed that MYD88 is an obligatory signalling intermediate 
for this pathway, and that it is augmented by TLR4 signaling. A role for TLR4 in 
experimental NASH receives strong support from other studies. For example, we and Li et al 
have shown it is part of a high mobility group box 1 (HMGB1) dependent feed-forward 
pathway of lipotoxic injury to hepatocytes in the early stages of NASH [34,48]. The 
mechanisms for interaction between TLR4 and NLRP3 include NF-B-dependent induction 
of NLRP3 and pro-IL-1. In turn, IL-1 binding its cognate receptor activates NF-B 
[16,22,44], leading to a vicious cycle of pro-inflammatory signalling. It remains possible that 
HMGB1 and other DAMPs activate both pathways simultaneously, but this requires further 
studies.  
 
Our results do not support the contention that NLRP3 influences metabolic disorder relevant 
to NASH pathogenesis [45,46]. Specifically, MCC950 did not alter body weight or the very 
high plasma insulin, fasting blood glucose, plasma cholesterol and low plasma adiponectin 
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levels in obese foz/foz mice, all of which contribute mechanistically to NASH [1,2,5-7]. The 
different conclusions reached by earlier workers may be due to the breeding of mice with a 
constitutive NLRP3 deletion leading to microbial dysbiosis [45,46], which is not seen when 
NLRP3 is inhibited in adult mice. Our data also fail to support a proposed role of IL-1 in 
contributing to hepatocyte fat deposition in NASH [17,49]. Instead, the beneficial effects of 
MCC950 inhibition against steatohepatitis were limited to abrogation of the pro-
inflammatory effects of hepatic NLRP3 activation, not to any effect on steatosis or 
cholesterol crystal deposition which remained unaltered.  
 
The operation of NLRP3 as a pathogenic mechanism in the MCD model indicates that 
cholesterol crystals are not the only pathway to inflammasome activation in steatohepatitis. 
Release of ATP from necrotic cells, HMGB1, histones, amyloid and uric acid crystals can 
each activate NLRP3 via separate but potentially overlapping pathways [15,18,21,22,44], 
while reactive oxygen species (ROS) and potassium ion fluxes are linked to the effector 
stages of NLRP3 activation [22]. We and others [42,44] have demonstrated that the 
predominant lipidomic abnormality in the MCD-fed mice is accumulation of saturated free 
fatty acids, differing from foz/foz mice and human NASH in which free cholesterol is the 
toxic lipid that distinguishes NASH from simple steatosis [30,38-41]. Saturated free fatty 
acids and free cholesterol both cause lipotoxicity via JNK1 activation [34,50], leading to 
mitochondrial injury with generation of ROS. Sources of oxidative stress have been 
characterized in the MCD model and in human NASH, such as induction of CYPs 2E1 and 
4A [32,33]. Whether ROS are sufficient to act alone as second signal (with LPS, TNF- or 
IL-1 as signal-1) or augment other inflammasome activators, such as ATP and cholesterol 
crystals, requires further study.  
 
Liver fibrosis predicts adverse liver outcomes in NAFLD [1-4], so an emphasis of these 
studies, was to establish whether NLRP3 inhibition reduces liver fibrosis in steatohepatitis. 
We tested this in two entirely different models [28], because several pathways may interact to 
promote hepatic fibrogenesis in steatohepatitis. NLRP3 inhibition may combat liver fibrosis 
because dampening liver inflammation lowers expression of pro-fibrotic cytokines and 
growth factors (TNF-, TGF-, CTGF), and IL-1 may be directly pro-fibrogenic [12,19,44]. 
Indeed, administration of anakinra, an IL-1 receptor antagonist, improved liver fibrosis in 
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experimental alcoholic hepatitis [17]. Our present results in MCD-fed mice demonstrate that 
MCC950, an orally available small molecule, affords substantial (though incomplete) 
protection against hepatic fibrosis when administered at the same time as the disease-
inducing diet over 6 weeks, and even when administered for 2 weeks of such a regimen there 
appears to be moderate (albeit not significant) reduction of collagen deposition. In the more 
protracted obese/diabetic foz/foz model, the 8-week data from 16 to 24 weeks complement 
this finding, and indicate the potential for NLRP3 inhibitor treatment to arrest or resolve of 
liver fibrosis once NASH is established. Further experiments with introduction of MCC950 
therapy at a later time, are required to determine to test the extent to which NLRP3 blockade 
reverses advanced stage liver fibrosis in NASH. 
 
In summary, we show here that MCC950, a first-in-class potent and specific NLRP3 
inhibitor, improves liver injury, substantially reduces hepatic infiltration with macrophages 
and neutrophils and modulates fibrotic progression of steatohepatitis in two different models. 
We demonstrated by tissue studies that these effects resulted from substantial reduction of 
NLRP3 activation in the liver. It remains possible that NLRP3 activation proceeds in concert 
with other pro-inflammatory pathways, such as lipotoxicity, oxidative stress and TLR4, but a 
role for NLRP3 and IL-1 on metabolic regulation and hepatic lipid deposition is not 
supported by the present findings. While the effect of MCC950 on NASH fibrosis in these 
models is encouraging, the full potential of inflammasome blockade may exceed what we 
observed here as MCC950, which is a test compound for proof-of-principal studies, does not 
have optimal pharmacokinetics for once a day oral dosing. Development of second 
generation NLRP3 inhibitors optimized for liver bioavailability and human use will allow 
testing of whether these agents provide pharmacological resolution of NASH, and whether 
this novel approach will reverse significant liver fibrosis, its most important outcome.  
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Legends to Figures.  
Fig. 1. Cholesterol crystals provoke IL-1 release and neutrophil recruitment by 
macrophages and Kupffer cells, which is inhibited by MCC950. (A) Effects of cholesterol 
crystals on IL-1 release for LPS-primed bone marrow macrophages (BMM) from wildtype 
(Wt), Tlr4
-/-
, and Myd88
-/-
 mice. (B) MCC950 (10 nM) inhibits IL-1 production from Wt 
BMMs. (C) Enriched culture medium from crystal activated BMMs stimulates neutrophil 
chemotaxis. (D) Cholesterol crystals stimulate IL-1 release from Kupffer cells, but (E) 
minimally in hepatocytes. *P<0.05 versus no crystals. 
∆
P<0.05 versus Wt. 
#
P<0.05 MCC950 
versus untreated, by Mann-Whitney U test, n=9-12. 
 
Fig. 2. Effects of conditions causing NASH on hepatic expression of NLRP3, pro-caspase 
1, active caspase 1, pro-IL-1 and IL-1. (A) NLRP3 in wildtype (Wt) and foz/foz mice 
after 24weeks atherogenic diet, and gavage during the last 8 weeks with vehicle (saline) or 
MCC950. (B) Hepatic pro-caspase 1 (p45), (C) active caspase 1 (p10), (D) pro-IL-1 (p30), 
and (E) IL-1 (p17). (F) Representative Western blot analyses from same experiments, with 
heat shock protein 90 (HSP90) as loading controls. *P<0.05 versus Wt. 
#
P<0.05 MCC950 
versus vehicle, by one-way ANOVA, n=6-10 animals/group. 
 
Fig. 3. Effects of MCC950 versus vehicle on circulating cytokines/chemokines and 
transaminases in mice with NASH. (A) Plasma IL-1 (B) Plasma IL-18, (C) ALT, (D) 
AST, (E) macrophage chemotactic protein 1 (MCP-1), (F) IL-6. Same mice as in Fig. 2. 
*P<0.05 or less versus Wt. 
#
P<0.05 MCC950 versus vehicle, by one-way ANOVA, n=11-13 
animals/group, same animals as in Fig. 2. 
 
Fig. 4. MCC950 reverses NASH pathology. (A) (i) Steatosis, (ii) hepatocyte ballooning, 
and (iii) NAFLD activity score (NAS) in Wt and foz/foz mice after 24weeks atherogenic diet, 
and gavage during last 8 weeks with vehicle or MCC950. (B) Representative H&E-stained 
liver sections demonstrating inflammation in atherogenic foz/foz mouse liver (vehicle) is 
abolished by MCC950, with reduction of lobular inflammation score. (C) NF-B activation 
(nuclear p65) is suppressed, as are, (D) myeloperoxidase [MPO]) positive neutrophils, and 
(E) F4/80 positive macrophages and Kupffer cells. Same experiments as Figs. 2 and 3. 
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*P<0.05 versus Wt. 
#
P<0.05 MCC950 versus vehicle, by one-way ANOVA, n=11-13 
animals/group. Scale bar: 100µm. 
 
Fig. 5. In MCD-fed mice MCC950 suppresses hepatic NLRP3 inflammasome activation, 
inflammatory cell infiltration and fibrosis. (A) Hepatic Asc, Casp1 and Il1b mRNA in 
mice fed MCD or MCS diets, and gavaged MCC950 or vehicle for 6 weeks. To right 
representative Western blot analyses of pro-caspase 1, active caspase 1, pro-IL-1and IL-1: 
GAPDH loading control. (B) Representative H&E-stained liver sections. To right number of 
infiltrating neutrophils and F4/80-positive cells. (C) Representative Sirius red-stained liver 
sections, and percentage fibrotic area. (D) mRNA expression of Col1a1, Ctgf and Timp1. 
Data: mean ± SEM, *P<0.05 MCS versus MCD, #P<0.05 vehicle versus MCC950 by one-
way ANOVA, n=8 animals/group. Scale bar: 100µm. 
 
Fig. 6. MCC950 suppresses liver fibrosis in obese, diabetic mice with NASH. (A) Sirius 
red-stained liver sections from Wt and foz/foz mice after 24 weeks atherogenic diet intake and 
gavage during the last 8 weeks with vehicle or MCC950 (same mice as in Figs. 2-4). (B) 
Collagen area by Sirius red densitometry. (C) Changes in collagen 1 (Col-1), (D) alpha-
smooth muscle actin (-SMA), (E) connective tissue growth factor (CTGF), and (F) 
representative Western blot analyses. Heat shock protein 90 (HSP90) as loading control. 
*P<0.05 or less versus Wt. 
#
P<0.05 MCC950 versus vehicle, by one-way ANOVA, n=6-10 
animals/group. Scale bar: 100µm. 
  
  
22 
 
 
 
  
  
23 
 
 
 
  
  
24 
 
 
 
  
  
25 
 
 
 
  
  
26 
 
 
 
  
  
27 
 
 
 
  
  
28 
 
 
Table 1. Global assessment of NAFLD pathology 
  
 
 
 
Groups n No 
Steatosis 
NAFLD, but 
not NASH 
Borderline 
NASH 
Definite  
NASH 
Wt Vehicle  13 9 (70%) 2 (15%) 2 (15%) 0 
Wt MCC950 12 5 (42%) 7 (58%) 0 0 
foz Vehicle 11 0 3 (27%) 1 (9.1%) 7 (64%) 
foz MCC950 11 0 7 (64%) 2 (18%) 2 (18%) 
  
SIGNAL 1:
LPS 
(via leaky gut)
NF-κB
SIGNAL 2:
Cholesterol crystals 
(from lipotoxic 
hepatocyes)
NLRP3 
Inflammasome
Caspase 1
IL-1β
proIL-1β
Reactive oxygen species
Cytokines 
Growth factors
HEPATOCYTES
HEPATIC 
STELLATE CELLS
NEUTROPHILS
KUPFFER CELLS/
MACROPHAGES
MCC950
Injury Inflammation Fibrosis
S   T   E   A   T   O   H   E   P  A  T  I   T   I   S
Phagasome
?
Steatosis
